Network Medicine

Blueprint for antimicrobial hit discovery targeting metabolic networks

Proceedings of the National Academy of Sciences of the United States of America 10.1073, 1-6 (2010) Advances in genome analysis, network biology, and computational chemistry have the potential to revolutionize drug discovery by combining system-level identification of drug targets with the atomistic modeling of small molecules capable of modulating their activity. To demonstrate the effectiveness of such a discovery pipeline, we deduced common antibiotic targets in Escherichia coli and Staphylococcus aureus by identifying shared tissue-specific or uniformly essential metabolic reactions in their metabolic networks. We then predicted through virtual screening dozens of potential inhibitors for several enzymes of these reactions and showed experimentally that a subset of these inhibited both enzyme activities in vitro and bacterial cell viability. This blueprint is applicable for any sequenced organism with high-quality metabolic reconstruction and suggests a general strategy for strain-specific antiinfective therapy.


More publications
A. Motter, N. Gulbahce, E. Almaas, A.-L. Barabási

Molecular Systems Biology 4:168, 1-10 (2008)

S. Wuchty, A.-L. Barabási, M.T. Ferdig

BMC Evolutionary Biology 60, 8 (2006)

A.L. Barabási

New England Journal of Medicine 357, 404-407 (2007)